|
rs17632542
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Previous research identified four single nucleotide polymorphisms (SNPs) principally associated with circulating PSA levels rather than with prostate cancer risk (TERT rs2736098, FGFR2 rs10788160, TBX3 rs11067228, KLK3 rs17632542).
|
26431041 |
2015 |
|
rs17632542
|
|
T |
0.750 |
GeneticVariation |
GWASDB |
When comparing prostate cancer cases with low PSA controls, alleles at genetic markers rs1512268, rs445114, rs10788160, rs11199874, rs17632542, rs266849, and rs2735839 were associated with an increased risk of prostate cancer, but the effect-estimates were attenuated to the null when using high PSA controls (Pheterogeneity in effect-estimates < 0.04).
|
24753544 |
2014 |
|
rs17632542
|
|
|
0.750 |
GeneticVariation |
BEFREE |
The genotypes of 4 single nucleotide polymorphisms previously associated with serum prostate specific antigen levels (rs2736098, rs10788160, rs11067228 and rs17632542) were determined in 964 healthy Caucasian volunteers without prostate cancer.
|
23246478 |
2013 |
|
rs17632542
|
|
|
0.750 |
GeneticVariation |
BEFREE |
The second locus was rs1354774 (P = 1.25 x 10(-12)), near KLK2 at 19q13, which was not associated with tPSA levels, and is separate from the rs17632542 locus at KLK3 that was previously associated with tPSA levels and prostate cancer risk.
|
23359319 |
2013 |
|
rs17632542
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We did not observe a strong association with the KLK3 variant, reported in previous studies to confer risk for prostate cancer (rs2735839; P = 0.20) but did observe three highly correlated SNPs (rs17632542, rs62113212 and rs62113214) associated with prostate cancer [P = 3.41 × 10(-4), per-allele trend odds ratio (OR) = 0.77, 95% CI = 0.67-0.89].
|
21318478 |
2011 |
|
rs17632542
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We propose that rs17632542 may directly influence PrCa risk.
|
21465221 |
2011 |
|
rs1058205
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The overall results indicated that polymorphism T>C of rs1058</span>205 was associated with decreased risk of PCa</span> (allele contrast: OR = 0.75, 95% CI = 0.64-0.88, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.42-0.81, <i>P</i><sub>heterogeneity</sub> < 0.001), particularly in Caucasian population (allele contrast: OR = 0.77, 95% CI = 0.65-0.91, <i>P</i><sub>heterogeneity</sub> < 0.001; homozygote comparison: OR = 0.58, 95% CI = 0.41-0.82, <i>P</i><sub>heterogeneity</sub> < 0.001).
|
30413614 |
2018 |
|
rs1058205
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The frequency of the TC genotype of rs1058205 in the PCa group was significantly lower than that in the control group (P = 0.049).
|
28272245 |
2017 |
|
rs1058205
|
|
|
0.720 |
GeneticVariation |
GWASDB |
Multiple newly identified loci associated with prostate cancer susceptibility.
|
18264097 |
2008 |
|
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In addition, no association was observed between polymorphism A>G of rs266882 and risk of PCa.
|
30413614 |
2018 |
|
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We evaluated the impact of genetic variation in the prostate-specific antigen (PSA) gene (rs266882) on serum PSA levels in healthy men as well as risk factors for benign prostate hypertrophy (BPH) and prostate cancer.
|
23315126 |
2013 |
|
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological features.
|
23235975 |
2012 |
|
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Meta-analysis of 12 studies of rs266882 and overall p</span>rostate cancer risk was null.
|
18827812 |
2008 |
|
rs266882
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Men homozygous or heterozygous for the G/G (rs925013/rs266882) haplotype were at higher risk of prostate cancer than men homozygous for the A/A haplotype (odds ratio, 1.3; 95% CI, 1.1-1.7; P = 0.009).
|
16775173 |
2006 |
|
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer.
|
18483391 |
2008 |
|
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk.
|
12042668 |
2002 |
|
rs149709822
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results suggest that the A49T mutation may influence the pathological characteristics of prostate cancers and, thus, may affect the prognosis of these patients.
|
10749132 |
2000 |
|
rs61752561
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs61752561 SNP appears to have a potential role in PCa pathogenesis by changing the glycosylation, protein stability, and PSA activity and may also affect the clinically measured F/T PSA ratio.
|
30538125 |
2019 |
|
rs61752561
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs61752561 in KLK3 and rs2735839 in the KLK2-KLK3 intergenic region were strongly associated with prostate cancer-specific survival, and rs10486567 in the 7JAZF1 gene were associated with biochemical recurrence.
|
20460480 |
2010 |
|
rs746367915
|
|
|
0.020 |
GeneticVariation |
BEFREE |
An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed.
|
21178268 |
2010 |
|
rs746367915
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This exploratory analysis in prostate cancer patients revealed the W allele of the KLK2 R250W SNP to be less likely associated with low GS morphology.
|
21178268 |
2010 |
|
rs746367915
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggest that the C allele of the functional C748T polymorphism of KLK2 may increase the risk of PCa.
|
15643194 |
2005 |
|
rs1192131078
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>).
|
30538125 |
2019 |
|
rs369223448
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation.
|
27509056 |
2016 |